Content
01/07/2025
Jerusalem Israel
Senseera
completed $7.1 million Seed Round funding. Investors include
Lightspeed Venture Partners (lead), I-Next Capital.
About
Senseera's GEM (Genomic Expression Maps) BIOMARKERS , a novel biomarker discovery platform based on a patent protected chromatin epigenomics (cfChIP-seq) liquid biopsy technology (Sadeh, Nature Biotechnology, 2021).
GEM BIOMARKERS turns a simple blood draw into unparalleled, quantitative, cell-specific gene expression, and regulation data from cell-free DNA. Going beyond traditional methods like cfDNA genomics and methylation, it offers a transformative layer of data for various applications including biomarker discovery, tissue-agnostic MRD detection, response to therapy, disease subtyping and more.
Backed by a database of over 20,000+ annotated disease samples and a diverse 2,000+ healthy subjects cohort , Senseera is collaborating with leading drug developers from big pharma and biotechs, to deliver mechanistic insights with exceptional sensitivity and specificity across multiple indications, advancing human health and precision medicine worldwide.
Startup
Sector:
Biotech
Life Science
Download StockFan App
Ad
Stock market data, news and community, all integrated.
Features include real time stock quotes, interactive charts, technical signals, institutional & insider ownerships, stock screener, ETF rankings, SEC filings, press releases, videos, earnings calendar, social media posts, group chats.
